NCT03322540: A reported trial by Incyte Corporation
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03322540 |
|---|---|
| Title | A Phase 2, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Versus Pembrolizumab Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1 |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 15, 2017 |
| Completion date | Jan. 10, 2019 |
| Required reporting date | Jan. 10, 2020, midnight |
| Actual reporting date | Jan. 6, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |